In pharmaceutical development, AI has the potential to enable faster, more cost-effective, and more efficient drug and drug–device development. Yet it is often viewed at the extremes, either as a regulatory risk or a silver bullet. In reality, it is neither. The real question is how the industry can apply AI in a way that is both scientifically robust and regulator-ready.
In our latest article published in Drug Development and Delivery, Bespak CTO Alan Harris explores how AI-driven modelling and simulation are already supporting respiratory drug and device development, and why AI is set to play an increasingly important role across the entire drug product development lifecycle.
Read the full article here.
